{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:30:24Z","timestamp":1791689424624,"version":"4.3.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.ijrobp.2008.10.043","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T04:55:42Z","timestamp":1232772942000},"page":"156-163","source":"Crossref","is-referenced-by-count":316,"title":["Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas"],"prefix":"10.1016","volume":"75","clinical-trial-number":[{"clinical-trial-number":"nct00595322","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Philip H.","family":"Gutin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio M.","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Beal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimish A.","family":"Mohile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasan","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob L.","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Lymberis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenghwa","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Abrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2008.10.043_bib1","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/0360-3016(80)90175-3","article-title":"Therapeutic irradiation and brain injury","volume":"6","author":"Sheline","year":"1980","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib2","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/0360-3016(79)90553-4","article-title":"An analysis of dose\u2013effect relationship in the radiotherapy of malignant gliomas","volume":"5","author":"Walker","year":"1979","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1053\/ctrv.2000.0191","article-title":"A comparison of treatment results for recurrent malignant gliomas","volume":"26","author":"Nieder","year":"2000","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib4","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrn2175","article-title":"Angiogenesis in brain tumours","volume":"8","author":"Jain","year":"2007","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib5","first-page":"1399","article-title":"Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A","volume":"9","author":"Lamszus","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1200\/JCO.2007.13.3652","article-title":"Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan","volume":"26","author":"Sathornsumetee","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib7","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/359845a0","article-title":"Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo","volume":"359","author":"Plate","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib8","first-page":"3374","article-title":"Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation","volume":"59","author":"Gorski","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1535-6108(04)00115-1","article-title":"Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules","volume":"5","author":"Moeller","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib10","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib11","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib12","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.2005.03.4645","article-title":"Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer","volume":"24","author":"Wedam","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib13","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-06-2309","article-title":"Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma","volume":"13","author":"Vredenburgh","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib14","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","article-title":"Bevacizumab plus irinotecan in recurrent glioblastoma multiforme","volume":"25","author":"Vredenburgh","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib15","doi-asserted-by":"crossref","first-page":"2010b","DOI":"10.1200\/jco.2008.26.15_suppl.2010b","article-title":"A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM)","volume":"28","author":"Cloughesy","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib16","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ijrobp.2007.02.001","article-title":"Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results","volume":"68","author":"Czito","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib17","doi-asserted-by":"crossref","first-page":"8136","DOI":"10.1200\/JCO.2005.02.5635","article-title":"Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a Phase I trial in rectal cancer patients","volume":"23","author":"Willett","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib18","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.ijrobp.2007.11.068","article-title":"Phase II pilot study of Bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: Interim analysis of safety and tolerability","volume":"71","author":"Lai","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2007.07.093","article-title":"Feasibility of using bevacizumab with radiation therapy in high grade gliomas","volume":"69","author":"Narayana","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccr.2007.11.032","article-title":"Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: Role of bone marrow-derived myelomonocytic cells","volume":"13","author":"Ahn","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib21","first-page":"39","article-title":"Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts","volume":"61","author":"Kozin","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib22","doi-asserted-by":"crossref","first-page":"7843","DOI":"10.1158\/0008-5472.CAN-06-1010","article-title":"Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor","volume":"66","author":"Bao","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ccr.2006.11.020","article-title":"A perivascular niche for brain tumor stem cells","volume":"11","author":"Calabrese","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib24","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1126\/science.1082504","article-title":"Tumor response to radiotherapy regulated by endothelial cell apoptosis","volume":"300","author":"Garcia-Barros","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib25","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/01.coc.0000145289.57705.07","article-title":"Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma","volume":"27","author":"Beitler","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.radonc.2006.11.023","article-title":"Image-guided robotic radiosurgery for spinal metastases","volume":"82","author":"Gibbs","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib27","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1080\/02841860600904870","article-title":"Interim analysis of a prospective Phase I\/II trial of SBRT for liver metastases","volume":"45","author":"Kavanagh","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib28","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.ijrobp.2003.11.004","article-title":"Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer","volume":"58","author":"Koong","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.lungcan.2005.08.011","article-title":"Stereotactic hypofractionated radiotherapy for Stage I non-small cell lung cancer\u2014mature results for medically inoperable patients","volume":"51","author":"Nyman","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0360-3016(96)00497-X","article-title":"Radiosurgery for brain metastases: Relationship of dose and pattern of enhancement to local control","volume":"37","author":"Shiau","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib31","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ijrobp.2007.11.046","article-title":"High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions","volume":"71","author":"Yamada","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib32","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijrobp.2008.02.003","article-title":"High-dose single-fraction radiotherapy: Exploiting a new biology?","volume":"71","author":"Brown","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib33","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nrc1946","article-title":"Predicting benefit from anti-angiogenic agents in malignancy","volume":"6","author":"Jubb","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib34","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for Phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib35","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/mrm.1910240119","article-title":"Measurement of blood-brain barrier permeability using dynamic Gd-DTPA scanning\u2014a comparison of methods","volume":"24","author":"Larsson","year":"1992","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000088637","article-title":"Neuroprotective role of vascular endothelial growth factor: Signalling mechanisms, biological function, and therapeutic potential","volume":"14","author":"Zachary","year":"2005","journal-title":"Neurosignals"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib37","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1200\/JCO.1999.17.8.2572","article-title":"Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials","volume":"17","author":"Wong","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2407-5-55","article-title":"Hypofractionated stereotactic re-irradiation: Treatment option in recurrent malignant glioma","volume":"5","author":"Vordermark","year":"2005","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib39","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.30.9.907","article-title":"Assumptions in the radiotherapy of glioblastoma","volume":"30","author":"Hochberg","year":"1980","journal-title":"Neurology"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib40","first-page":"723","article-title":"Retardation of tumor growth in mice caused by radiation-induced injury of tumor bed stroma: Dependency on tumor type","volume":"46","author":"Milas","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib41","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/nrc925","article-title":"Vascular and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy?","volume":"2","author":"Rafii","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","article-title":"AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients","volume":"11","author":"Batchelor","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib43","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","article-title":"Tumor angiogenesis","volume":"358","author":"Kerbel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib44","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ijrobp.2006.10.030","article-title":"Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice","volume":"67","author":"Itasaka","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib45","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1158\/0008-5472.CAN-06-3664","article-title":"Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors","volume":"67","author":"Kozin","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib46","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/jmri.10072","article-title":"Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme","volume":"15","author":"Gossmann","year":"2002","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib47","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.molmed.2007.04.001","article-title":"VEGF-targeted cancer therapy strategies: Current progress, hurdles and future prospects","volume":"13","author":"Duda","year":"2007","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.ijrobp.2008.10.043_bib48","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1126\/science.6823562","article-title":"Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid","volume":"219","author":"Senger","year":"1983","journal-title":"Science"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301608036882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301608036882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T10:23:58Z","timestamp":1558088638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301608036882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0360301608036882"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2008.10.043","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}